Search results
Results from the WOW.Com Content Network
Phenylephrine, sold under the brand names Neosynephrine and Sudafed PE among others, is a medication used as a decongestant for uncomplicated nasal congestion in the form of a nasal spray or oral tablet, [5] to dilate the pupil, to increase blood pressure given intravenously in cases of low blood pressure, and to relieve hemorrhoids as a suppository.
Phenylephrine is found in a wide range of cold and flu medications, including Sudafed PE, Benadryl Allergy D Plus Sinus and Vicks DayQuil Cold and Flu Relief. Here’s what experts say are ...
Phenylephrine is an oral medication primarily used as a decongestant. [5] [6] It is a selective α 1-adrenergic receptor activator which results in the constriction of both arteries and veins. [5] Common side effects include nausea, headache, and anxiety. [5] Phenylephrine was patented in 1927 and came into medical use in 1938. [7]
On Nov. 7, the Food and Drug administration announced a proposal to remove oral phenylephrine — a decongestant found in products by brands including Sudafed PE, Vicks DayQuil and Theraflu ...
Concomitant use of pseudoephedrine with other vasoconstrictors, including ergot alkaloids like ergotamine and dihydroergotamine, linezolid, oxytocin, ephedrine, phenylephrine, and bromocriptine, among others, is not recommended due to the possibility of greater increases in blood pressure and risk of hemorrhagic stroke. [1]
When two drugs affect each other, it is a drug–drug interaction (DDI). The risk of a DDI increases with the number of drugs used. [1] A large share of elderly people regularly use five or more medications or supplements, with a significant risk of side-effects from drug–drug interactions. [2] Drug interactions can be of three kinds:
It contains phenylephrine and ketorolac. [ 1 ] Phenylephrine/ketorolac was approved for medical use in the United States in May 2014, [ 4 ] and in the European Union in July 2015.
The mechanisms of sympathomimetic drugs can be direct-acting (direct interaction between drug and receptor), such as α-adrenergic agonists, β-adrenergic agonists, and dopaminergic agonists; or indirect-acting (interaction not between drug and receptor), such as MAOIs, COMT inhibitors, release stimulants, and reuptake inhibitors that increase the levels of endogenous catecholamines.